CA2178504C - Immunodosages relatifs a l'antigene specifique de la prostate - Google Patents

Immunodosages relatifs a l'antigene specifique de la prostate Download PDF

Info

Publication number
CA2178504C
CA2178504C CA002178504A CA2178504A CA2178504C CA 2178504 C CA2178504 C CA 2178504C CA 002178504 A CA002178504 A CA 002178504A CA 2178504 A CA2178504 A CA 2178504A CA 2178504 C CA2178504 C CA 2178504C
Authority
CA
Canada
Prior art keywords
analyte
alpha
binding molecule
antibody
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002178504A
Other languages
English (en)
Other versions
CA2178504A1 (fr
Inventor
Barry L. Dowell
Carol A. King
Debra B. Alexander
Allan H. Smith
Susan B. O'morchoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/174,964 external-priority patent/US5599677A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to CA002546529A priority Critical patent/CA2546529A1/fr
Publication of CA2178504A1 publication Critical patent/CA2178504A1/fr
Application granted granted Critical
Publication of CA2178504C publication Critical patent/CA2178504C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un immunodosage auquel on fait appel en cancérologie. De façon spécifique, un nouveau procédé d'immunodosage relatif à l'antigène spécifique de la prostate (PSA) est décrit. L'invention concerne également un complexe qui ressemble au complexe PSA et .alpha.-antichymotrypsine (ACT) qui peut être utilisé comme élément d'étalonnage ou témoin dans un immunodosage relatif au PSA. Est également décrit un procédé permettant de séparer, parmi des anticorps polyclonaux dirigés contre le PSA, ceux qui fixent des épitopes qui sont masqués par la liaison du PSA à l'ACT de ceux qui ne fixent pas de tels épitopes.
CA002178504A 1993-12-29 1994-12-22 Immunodosages relatifs a l'antigene specifique de la prostate Expired - Lifetime CA2178504C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002546529A CA2546529A1 (fr) 1993-12-29 1994-12-22 Dosages immunologiques pour la detection d'un antigene prostatique specifique

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/174,964 1993-12-29
US08/174,964 US5599677A (en) 1993-12-29 1993-12-29 Immunoassays for prostate specific antigen
PCT/US1994/014902 WO1995018381A1 (fr) 1993-12-29 1994-12-22 Immunodosages relatifs a l'antigene specifique de la prostate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002546529A Division CA2546529A1 (fr) 1993-12-29 1994-12-22 Dosages immunologiques pour la detection d'un antigene prostatique specifique

Publications (2)

Publication Number Publication Date
CA2178504A1 CA2178504A1 (fr) 1995-07-06
CA2178504C true CA2178504C (fr) 2006-09-05

Family

ID=36968348

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002178504A Expired - Lifetime CA2178504C (fr) 1993-12-29 1994-12-22 Immunodosages relatifs a l'antigene specifique de la prostate

Country Status (1)

Country Link
CA (1) CA2178504C (fr)

Also Published As

Publication number Publication date
CA2178504A1 (fr) 1995-07-06

Similar Documents

Publication Publication Date Title
EP0741868B1 (fr) Immunodosages relatifs a l'antigene specifique de la prostate
US5939533A (en) Assay of free and complexed prostate-specific antigen (PSA)
JP4274330B2 (ja) ｃＰＳＡの測定方法
Amiral et al. Application of enzyme immunoassays to coagulation testing.
US20020106708A1 (en) Assays reagents and kits for detecting or determining the concentration of analytes
Yu et al. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies
Oh et al. Point-of-care fluorescence immunoassay for prostate specific antigen
US5840501A (en) Determination of cPSA
US7211397B2 (en) Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6379550B1 (en) Method for detecting PSA and its molecular forms using thiophilic gel
US6107103A (en) Assay for PSP94 protein
US6692643B2 (en) Method for detecting PSA and its molecular forms using thiophilic gel on magnetic beads
JPH02259570A (ja) 骨由来アルカリホスファターゼの検定法
JP4755112B2 (ja) 抗原を測定するための試薬及び抗原の測定方法
Vihko et al. Time-resolved immunofluorometric assay of human prostate-specific antigen
JPH0580053A (ja) ヒト子宮体癌細胞の免疫化学的検出方法
US5587291A (en) Method for the determination of plasmin α2 -antiplasmin complexes and the use of this method as a mean of determining changes in the fibrinolytic system
CA2546529A1 (fr) Dosages immunologiques pour la detection d'un antigene prostatique specifique
Matsumoto et al. ELISA for a complexed antigen with a monoclonal antibody blocking reaction with the free antigen—assay-specific for complexed prostate-specific antigen
US5601988A (en) Immunocapture assay for cancer procoagulant antibody complex in biological samples
CN113866426A (zh) 一种检测d-二聚体的试剂盒及其制备方法
Tillyer et al. Disagreement between the Roche Cobas® core and hybritech TANDEM®-E PSA assays when measuring free, complexed and total serum prostate specific antigen
JP2000266747A (ja) 抗ラットＩｇＥ抗体を用いたラットＩｇＥの測定キット及び測定方法
JPH0643167A (ja) 癌マーカーであるテネイシン及びその定量法
KUROBE et al. Development of monoclonal antibody-based enzyme immunoassay for human pancreatic secretory trypsin inhibitor (PSTI) suitable for clinical tests

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20141222